The problem of remission in schizophrenia: Clinical and epidemiological study

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 107, Issue 5, 2007, Pages 4-15

  Smulevich, A B ^a   Andryushchenko, A V ^a   Beskova, D A ^a  

^a NONE

Author keywords

Clinical systematics; Remission; Schizophrenia; Therapeutic aproaches

Indexed keywords

EID: 34547916466     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Russian source
2. Russian source
3. Russian source
4. Russian source
5. Russian source
6. Russian source
7. Russian source
8. Russian source
9. Russian source
10. Russian source
11. Russian source
12. Russian source
13. Russian source
14. Russian source
15. Russian source
16. Russian source
17. Russian source
18. Russian source
19. Russian source
20. Russian source
21. Russian source
22. Russian source
23. Russian source
24. Russian source
25. Russian source
26. Russian source
27. Andreasen N.C. et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiat 2005; 162: 3: 441-449.
28. Andersson C.M. et al. Emerging roles for novel antipsychotic medications in the treatment of schizophrenia. Psychiat Clin North Am 1998; 21: 1: 151-179.
29. Bleuler E. Dementia praecox of the group of schizophrenias. New York: International Universities Press 1911; 1950.
30. Bleuler M. The schizophrenic disorders: long-term patient and family studies. New Haven: Yale University Press 1978.
31. Bleuler M. A 23-year longitudinal study of 208 schizophrenics and impressions in regard to the nature of schizophrenia, in the transmission of schizophrenia. D. Rosental, S.S. Kety (eds.). Oxford: Pergamon 1968.
32. Davis J.M. et al. A meta-analysis of the efficacy of second-generation anti psychotics. Arch Gen Psychiat 2003; 60: 553-564.
33. de Leon J., Simpson G.M. Do schizophrenic negative symptoms respond to neuroleptics? Integr Psychiat 1991; 7: 39-47.
34. Dunayevich E. et al. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes. Schizophr Res 2006; 86: 300-308.
35. Endicolt J. et al. The Global Assessment of Functioning scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiat 1976; 33: 766-771.
36. Jobe T.H., Harrow M. Long-term outcome of patients with schizophrenia: a review. Can J Psychiat 2005; 50: 892-900.
37. Harrison, Glynn, Hopper K. et al. Recovery from Psychotic Illness: A 15- and 25-Year Intenation Follow-up study. Br J Psychiat 2001; 178: 506-517.
38. Harrow M., Jobe T.H. Longitudinal studies of outcome and recovery in schizophrenia and early intervention: can they make a difference? Canadian J Psychiat 2005; 50: 14: 879-880.
39. Ho B.C. et al. Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. Am J Psychiat 2000; 157: 808-815.
40. Kraepelin E. Psychiatrie, 8 Aufl. Leipzig 1913; 3: 667-1022.
41. Kraepelin E. Dementia praecox and paraphrenia. New York: E. Robert. Krieger Publishing Company Inc 1971.
42. Kolle K. Psychiatrie: ein Lehrbuch fur studierende und arzte. Stutgard 1961; 182-191.
43. Lader M. Neuroleptic-induced syndrome. Historical introduction. Acta Psychiat Scand 1994; 380: 6-7 (Suppl).
44. Lambert M. Pharmacopsychiatry 2003; 36: Suppl 3: 181-190.
45. Langfeldt G. Diagnosis and prognosis of schizophrenia. Proceedings Royal Society Med 1960; 53: 1047-1052.
46. Leucht S., Lasser R. The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry 2006; 39: 5: 161-170.
47. Liberman J.A. Is Schizophrenia a Neurodegenerative Disorder? A clinical and Neurobiological Perspective. Biol Psychiat 1999; 46: 6: 729-739.
48. Liberman I.A. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiat 2000; 57: Suppl 11: 68-71.
49. Liberman R., Kopelowicz A. Recovery from schizophrenia: a challenge for the 21 st century. Int Rev Psychiat 2002; 14: 515-540.
50. Liberman R., Kopelowicz A. Recovery from schizophrenia: a concept in search of research. Psychiat Servises 2006.
51. Marder S.R. et al. Dosing and switching strategies for long-acting risperidone. J Clin Psychiat 2003; 64: Suppl: 43-51.
52. Mason P. et al. The course of schizophrenia over 13 years. A report from the international study on schizophrenia (ISoS) coordinated by the World Health Organization. Br J Psychiat 1996; 169: 580-586.
53. Modestin J. et al. Chronic schizophrenia. Am J Psychiat 2003; 160: 3: 2202-2208.
54. Murphy B.P. et al. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 2006; 88: 5-25.
55. Moller H.J. et al. A path-analytical approach to differentiate between direct and indirect effects on negative symptoms in schizophrenia: a re-evaluation of the North American risperidone study. Eur Arch Psychiat Clin Neurosci 1995; 245: 45-49,
56. Moller H.J. Atypical neuroleptics: a new approch in the treatment of negative symptom. Eur Arch Psychiat Clin Neurosci 2004; 249: Suppl 4: 99-107.
57. Robinson D.G. et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiat 2004; 161: 3: 473-479.
58. Ruggeri M., Lasalvia A., Tansella M. et al. Heterogtnity of outcomes in schizophrenia. Br J Psychiat 2004; 184: 48-57.